Keel Point LLC Buys 49 Shares of Eli Lilly and Company (NYSE:LLY)

Keel Point LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,060 shares of the company’s stock after acquiring an additional 49 shares during the quarter. Keel Point LLC’s holdings in Eli Lilly and Company were worth $1,201,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $3,416,206,000. International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the period. Moneta Group Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares during the period. Morgan Stanley increased its position in shares of Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Finally, Imprint Wealth LLC increased its position in shares of Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after buying an additional 1,747,946 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 0.0 %

Eli Lilly and Company stock traded down $0.11 during mid-day trading on Monday, reaching $751.53. 1,468,437 shares of the company traded hands, compared to its average volume of 3,081,020. The firm’s 50 day moving average price is $761.77 and its 200 day moving average price is $654.08. The firm has a market capitalization of $714.07 billion, a price-to-earnings ratio of 130.01, a P/E/G ratio of 1.65 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.09 EPS. On average, analysts anticipate that Eli Lilly and Company will post 12.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on LLY shares. Barclays increased their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 133,785 shares of company stock valued at $86,537,034 in the last three months. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.